Levy Adam D. 4
4 · Acrivon Therapeutics, Inc. · Filed Apr 3, 2025
Insider Transaction Report
Form 4
Levy Adam D.
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-04-01+35,209→ 35,209 totalExercise: $1.68Exp: 2035-03-31→ Common Stock (35,209 underlying)
Footnotes (1)
- [F1]Twenty-five percent (25%) of the shares subject to the option vest on April 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.